A Comprehensive Review of the Renal Safety And Stability of Torsemide in Patients with Chronic Kidney Disease and Heart Failure

Loop diuretics are commonly used in clinical practice for the treatment of fluid overload states associated with
chronic kidney disease, congestive heart failure, and liver cirrhosis. These diuretics exert their action by
inhibiting the reabsorption of sodium and chloride ions in the thick ascending limb of the loop of Henle, thus
inducing diuresis and reducing extracellular fluid volume. Among all loop diuretics, torsemide and furosemide
are commonly used in clinical practice. These two drugs, although belonging to the same pharmacological class,
have shown significant differences in their pharmacokinetics, bioavailability, action, and clinical effects. Despite
all the above-mentioned beneficial effects of torsemide, there is limited prospective clinical data on the effects of
torsemide on various parameters of renal function, including GFR, serum creatinine, and BUN.
This review article aims to summarize the existing evidence of the efficacy of torsemide therapy and its effect on
renal function in patients with CKD and heart failure. It also aims to present a prospective interventional study
that will assess the effect of torsemide on renal function parameters, such as GFR, serum creatinine, and BUN. In
addition, the study will also assess the renal safety of the drug, including acute kidney injury and electrolyte
imbalance. In conclusion, this review article presents the potential role of torsemide as a safe and effective loop
diuretic that may help maintain a stable renal function while effectively treating fluid overload in patients with
cardiovascular and renal diseases.